








# ATTENTION ON ADHD: THE VALUE OF IMPROVING CARE FOR PEOPLE WITH ADHD SNAPSHOT



## Spain

### Overview of the ADHD Landscape in Spain

 <b>COUNTRY CONTEXT</b>	 <b>DISEASE BURDEN/EPIDEMIOLOGY</b>	 <b>ADHD RESEARCH</b>
<b>Population</b> <b>47,557,490<sup>1</sup></b>	<b>ADHD prevalence rate for adults (18-65)</b> <b>2.5%<sup>5</sup></b> <b>(756,420 patients)<sup>6 **</sup></b>	<b>Number of clinical trials</b> <b>14<sup>7</sup></b> <b>(from 01.08.12 to 01.08.22)</b>
<b>Current health expenditure</b> <b>(% of GDP)</b> <b>9.13%<sup>2</sup></b>	<b>REGISTRIES</b> <b>Is there a ADHD registry</b> <b>in the country?</b> <input checked="" type="checkbox"/> <b>NO</b>	<b>EUROPEAN ORGANISATION</b>  <a href="#">ADHD Europe</a>  <b>ADHD EUROPE</b> <small>CREATING AWARENESS OF AD/HD</small>
<b>Domestic general government</b> <b>health expenditure (% of GDP)</b> <b>6.45<sup>3</sup></b>	<b>REFERENCE CENTRES</b> <b>Number of reference centres</b> <b>/ centres of excellence</b> <input type="checkbox"/> <b>NO INFO</b>	<b>NATIONAL ORGANISATION</b> <b>FEAADAH</b>
<b>Out-of-pocket expenditure (%)</b> <b>21.81<sup>4</sup></b>		<b>NATIONAL GUIDELINES</b> <a href="#">Spanish guidelines</a> <input checked="" type="checkbox"/> <b>YES</b>

<sup>1</sup> World Population in Review. Spain Population (estimate on 31 August) Available at: <https://worldpopulationreview.com/countries/spain-population> Last accessed October 2022.

<sup>2</sup> The World Bank. Current Health expenditure (% of GDP) - Spain. Available at: <https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=ES> Last accessed October 2022.

<sup>3</sup> The World Bank. Domestic general government health expenditure (% of GDP) - Spain. Available at: <https://data.worldbank.org/indicator/SH.XPD.GHED.GD.ZS?locations=ES> Last accessed October 2022.

<sup>4</sup> The World Bank. Out-of-pocket expenditure (% of current health expenditure) - Spain. Available at: <https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=ES> Last accessed October 2022.

<sup>5</sup> Faraone S V., Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. *Neurosci Biobehav Rev.* 2021 Sep 1;128:789-818.

<sup>6</sup> Instituto Nacional de Estadística. Población residente por fecha, sexo y edad(31304) [Internet]. [cited 2022 Jul 8]. Available from: <https://www.ine.es/jaxiT3/Datos.htm?t=31304>

<sup>7</sup> EU Clinical Trials Register. Last accessed November 2022. Available at: <https://www.clinicaltrialsregister.eu/>

\*Treating to 70% of the estimated prevalence of patients means increasing rates of diagnosis meaning that the percentage of patients increases by 30% from 40-70 leading to a higher number of patients being treated in the health system).

\*\*Adult patient population is calculated by multiplying the ADHD prevalence rate from Faraone et al, 2021 by the country's 18-65 population data (see endnotes).